Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Hospital Acquired Infections Therapeutic Market, By Drug Class
7.1. Hospital Acquired Infections Therapeutic Market, By Drug Class Type, 2020-2030
7.1.1. Antibacterial Drugs
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. Antiviral Drugs
7.1.2.1. Market Revenue and Forecast (2016-2030)
7.1.3. Antifungal Drugs
7.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Hospital Acquired Infections Therapeutic Market, By Application
8.1. Hospital Acquired Infections Therapeutic Market, by Application, 2020-2030
8.1.1. Urinary Tract Infections
8.1.1.1. Market Revenue and Forecast (2016-2030)
8.1.2. Ventilator-associated Pneumonia
8.1.2.1. Market Revenue and Forecast (2016-2030)
8.1.3. Surgical Site Infections
8.1.3.1. Market Revenue and Forecast (2016-2030)
8.1.4. Bloodstream Infections
8.1.4.1. Market Revenue and Forecast (2016-2030)
8.1.5. Other Hospital Infections
8.1.5.1. Market Revenue and Forecast (2016-2030)
Chapter 9. Global Hospital Acquired Infections Therapeutic Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, By Drug Class (2016-2030)
9.1.2. Market Revenue and Forecast, by Application (2016-2030)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, By Drug Class (2016-2030)
9.1.3.2. Market Revenue and Forecast, by Application (2016-2030)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, By Drug Class (2016-2030)
9.1.4.2. Market Revenue and Forecast, by Application (2016-2030)
9.2. Europe
9.2.1. Market Revenue and Forecast, By Drug Class (2016-2030)
9.2.2. Market Revenue and Forecast, by Application (2016-2030)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, By Drug Class (2016-2030)
9.2.3.2. Market Revenue and Forecast, by Application (2016-2030)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, By Drug Class (2016-2030)
9.2.4.2. Market Revenue and Forecast, by Application (2016-2030)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, By Drug Class (2016-2030)
9.2.5.2. Market Revenue and Forecast, by Application (2016-2030)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, By Drug Class (2016-2030)
9.2.6.2. Market Revenue and Forecast, by Application (2016-2030)
9.3. APAC
9.3.1. Market Revenue and Forecast, By Drug Class (2016-2030)
9.3.2. Market Revenue and Forecast, by Application (2016-2030)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, By Drug Class (2016-2030)
9.3.3.2. Market Revenue and Forecast, by Application (2016-2030)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, By Drug Class (2016-2030)
9.3.4.2. Market Revenue and Forecast, by Application (2016-2030)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, By Drug Class (2016-2030)
9.3.5.2. Market Revenue and Forecast, by Application (2016-2030)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, By Drug Class (2016-2030)
9.3.6.2. Market Revenue and Forecast, by Application (2016-2030)
9.4. MEA
9.4.1. Market Revenue and Forecast, By Drug Class (2016-2030)
9.4.2. Market Revenue and Forecast, by Application (2016-2030)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, By Drug Class (2016-2030)
9.4.3.2. Market Revenue and Forecast, by Application (2016-2030)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, By Drug Class (2016-2030)
9.4.4.2. Market Revenue and Forecast, by Application (2016-2030)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, By Drug Class (2016-2030)
9.4.5.2. Market Revenue and Forecast, by Application (2016-2030)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, By Drug Class (2016-2030)
9.4.6.2. Market Revenue and Forecast, by Application (2016-2030)
9.5. Latin America
9.5.1. Market Revenue and Forecast, By Drug Class (2016-2030)
9.5.2. Market Revenue and Forecast, by Application (2016-2030)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, By Drug Class (2016-2030)
9.5.3.2. Market Revenue and Forecast, by Application (2016-2030)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, By Drug Class (2016-2030)
9.5.4.2. Market Revenue and Forecast, by Application (2016-2030)
Chapter 10. Company Profiles
10.1. Merck & Co., Inc.
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Pfizer Inc.
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Bayer AG
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. GlaxoSmithKline Plc.
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Daiichi Sankyo Company, Limited
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. AbbVie Inc.
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Abbott Laboratories
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. F. Hoffmann-La Roche Ltd
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. Allergan Plc.
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
Glossary of Terms